Form 8-K Salarius Pharmaceuticals For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Clear Street Starts Forgent Power Solutions (FPS) at Buy
Salarius Pharmaceuticals faces Nasdaq delisting over stock price
January 2, 2026 5:16 PM ESTSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX) received notice from Nasdaq on December 31, 2025, stating the company fails to meet minimum bid price requirements for continued listing on The Nasdaq Capital Market.
The company's stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq... More



